从诊断到疾病分期:多发性硬化脑脊液分子检测的多中心验证
该多中心研究回顾性分析160例疑似神经免疫疾病患者的脑脊液样本,其中96例确诊多发性硬化(MS)并随访至少3年,外部验证既往发表的脑脊液诊断与预后分类器。结果显示脑脊液分子诊断测试区分MS与其他神经疾病AUC达0.94,区分复发缓解型与进展型MS的AUC为0.76,预后分类器可预测随访EDSS评分(rho=0.43)。
要点
- 脑脊液分子诊断测试可高精度区分MS与其他炎症/非炎症神经疾病(AUC 0.94)。
- 该测试可区分复发缓解型与进展型MS(AUC 0.76)。
- 预后分类器能预测随访EDSS评分,提示可辅助个体化分层。
核心结论
- 脑脊液分子检测可在真实世界稳健区分MS与其他神经疾病、分层MS亚型并预测未来残疾进展。
研究设计与样本
- 多中心回顾性研究分析160例疑似神经免疫疾病患者的冻存脑脊液样本。
- 其中96例确诊MS并随访至少3年,用于外部验证既往发表的脑脊液诊断与预后分类器。
主要发现
- 诊断测试区分96例确诊MS与30例其他炎症性神经疾病及34例非炎症性神经疾病,AUC为0.94(p=4.7×10-21)。
- 测试区分65例复发缓解型MS与31例进展型MS,AUC为0.76(p=1.4×10-5)。
- 预后分类器预测随访时测得的EDSS评分(rho=0.43,p=2.54×10-5)。
关键数值与推荐
- 诊断测试区分MS与其他神经疾病AUC 0.94(p=4.7×10-21)。
- 亚型区分AUC 0.76(p=1.4×10-5)。
- 预后分类器与随访EDSS相关rho=0.43(p=2.54×10-5)。
临床怎么用
- 脑脊液分子检测有望在MS诊断时辅助区分其他神经疾病并识别进展型亚型。
- 预后分类器可提供未来残疾进展信息,为个体化治疗决策提供参考。
局限性
- 回顾性研究设计,样本来自疑似神经免疫疾病诊断评估人群。
- 随访队列仅96例确诊MS,样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The growing demand for personalized treatment in multiple sclerosis (MS) highlights the need for more precise biomarkers that can outperform magnetic resonance imaging and clinical assessment in patient stratification. Advances in multiplex proteomic technologies suggest that cerebrospinal fluid (CSF) analysis at MS onset may not only improve diagnostic accuracy, but also offer prognostic and staging information, as well as insight into molecular therapeutic targets. METHODS: This multicenter study retrospectively analyzed cryopreserved CSF samples from 160 individuals undergoing diagnostic evaluation for possible neuroimmunological disorder, and among these, followed a cohort of 96 people with confirmed MS for at least 3 years. The goal was to externally validate previously published CSF-based diagnostic and prognostic classifiers. RESULTS: Upon unblinding, the CSF-based molecular diagnostic test distinguished 96 people with confirmed MS from 30 individuals with other inflammatory neurological diseases, and 34 individuals with non-inflammatory neurological diseases, achieving an area under the receiver operating characteristic curve of 0.94 (p = 4.7 × 10-21). The test also differentiated 65 individuals with relapsing-remitting MS from 31 individuals with progressive MS, with an area under the receiver operating characteristic curve of 0.76 (p = 1.4 × 10-5). The prognostic classifier predicted prospectively measured Expanded Disability Status Scale scores at follow up (rho = 0.43, p = 2.54 × 10-5). INTERPRETATION: This multicenter external validation study demonstrates that CSF-based molecular tests can robustly distinguish MS from other neurological conditions, stratify MS subtypes, and predict future disability progression in real-world settings. These results lay the groundwork for development of next-generation molecular tools to personalize care in MS. ANN NEUROL 2026;99:328-340.
引用
- Ghezzi L, Kosa P, Greenwood M, et al. From Diagnosis to Disease Staging: Multisite Validation of Cerebrospinal Fluid Molecular Tests in Multiple Sclerosis. Ann Neurol. 2025. PMID: 41041831. doi:10.1002/ana.78047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。